Published in
American Society of Hematology, Blood, 13(126), p. 1595-1600, 2015
DOI: 10.1182/blood-2015-03-636761
Links
- ORCID
- ORCID
- American Society of Hematology | PDF
- ORCID
- [europepmc.org] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis based on metabolomics data
Journal article published in 2015 by
Hiroshi Deguchi,
Yajnavalka Banerjee 
,
Sunia Trauger,
Gary Siuzdak ,
Ewa Kalisiak,
José A. Fernández,
Linh Hoang,
Minerva Tran,
Subramanian Yegneswaran,
Darlene J. Elias,
John H. Griffin
,
Sunia Trauger,
Gary Siuzdak ,
Ewa Kalisiak,
José A. Fernández,
Linh Hoang,
Minerva Tran,
Subramanian Yegneswaran,
Darlene J. Elias,
John H. Griffin
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key PointsUntargeted and targeted metabolomics showed association of low plasma acylcarnitines levels with venous thrombosis risk. Long-chain acylcarnitines are anticoagulants that inhibit factor Xa by binding to factor Xa outside the γ-carboxy glutamic acid domain.